ConferenceSeries Ltd invites all the participants from all over the world to attend “2nd International Conference on Antimicrobial Agents and Chemotherapy” a two day international conference on 8thy and 9^th of December 2016 at San Antonio, Texas, USA which includes prompt Keynote presentations, Oral talks, Poster presentations and Exhibitions.

Chemotherapy 2016 will focus on the latest databases, curation and research done in each and every area of the cancer and its therapy which will help patients to get relief.  This conference series will involve burning topics related to Antimicrobial Agents and Chemotherapy mentioned in the conference series tracks and sub tracks. Through this chemotherapy meeting it will offer a unique opportunity for participants, investigators globally to meet, network, and perceive new scientific interactions in transfusion symposiums. Antimicrobial Agents and Chemotherapy2016 will comprise various leading keynote speakers and session speakers who will be delivering their speech on the current research topics of anti-cancer drug development, clinical research on cancer, immunology and vaccines, Chemotherapy Protocols, Advancement in the field of radiopharmaceuticals for treatment of cancer, Treatment of Lymphoma and Leukemias and on novel drug delivery systems for treating cancer. The young researchers and the student participants will gain the opportunity to grab the Best Poster Award by presenting their work as a poster presentation through our Young Researcher Forum in this melanin meeting.

ConferenceSeries Ltd organizes conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publish 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend???

With members from around the world focused on learning about Antimicrobial Agents & Chemotherapy and its advances; this is your best opportunity to reach the largest clambake of participants from the Antimicrobial agents and Chemotherapy community.  A life time opportunity to Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Chemotherapy are hallmarks of this conference.

Target Audience:

*) Antimicrobial Agents & Chemotherapy Students, Scientists

*) Antimicrobial Agents & Chemotherapy Researchers

*) Antimicrobial Agents & Chemotherapy Professors from medical colleges

*) Chemotherapy Associations and Societies

*) Business Entrepreneurs

*) Training Institutes

Cancer Breakthrough news that OVARIAN cancer patients could benefit more from new immunotherapy drugs if they are administered straight after chemotherapy has led scientists to research more in the field of Cancer Immunotherapy. Similarly Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). There is the need of new therapy protocol and system to mitigate poor prognosis in chemotherapy resistant lymphoma patients.

            According to IMS Health Holdings, the oncology therapeutic market, strengthening with the global spending on drugs, is expected to surpass $150 billion by 2020. The drastic hike is due to the launch of new novel therapies that are directly related to the immune system. Bristol-Myers Squibb Co and Merck along with other companies are putting in their diligent efforts to develop new molecules for the management and treatment of multiple ailments of oncology. Over the last five years, the cost of the oncology drugs rose to 72% in the US, which contributes to $15.9 billion. Going further, the biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2016 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.

            Geographically, North America, dominates the market followed by Europe. North America accounted for about 38% share in the overall oncology drugs market in 2016 owing to the heavy investments by multinational companies in research and development of cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.

            Why it’s in San Antonio, Texas, USA?

Chemotherapy confers a large burden in the United States. Several evidence-based interventions are available to reduce the incidence, morbidity, and mortality from these cancers. The National Comprehensive Chemotherapy Control Program (NCCCP) is uniquely positioned to implement these interventions in the US population. It is estimated that there will be about 91,000 new cases diagnosed and approximately 28,000 deaths from cancer in the United States during 2016.

Members Associated with Chemotherapy Research

Chemotherapy research associated members in Dallas are about 418, in USA 5684 members and worldwide about 10214 research members.

Hospitals Associated with Chemotherapy Research

Major Chemotherapy associated hospitals in San Antonio are around 2% when compared to worldwide. Hospitals in San Antonio and USA are:

Baylor University Medical Center

UT Southwestern Medical Center

Texas Health Presbyterian Hospital Dallas

Medical City Dallas Hospital

Plaza Medical Center

Texas Health Harris Methodist Hospital Fort Worth

Medical Center of Plano

Parkland Memorial Hospital

Baylor All Saints Medical Center at Fort Worth

Societies Associated with Chemotherapy Research

In world there are about 9,685 societies which are specifically associated with Gynecologic oncology, in which 1289 societies are from USA and the remaining 269 societies are from Dallas.

American Chemotherapy society

National cancer institute

Society of Chemotherapy

International Chemotherapy society

American college of Phlebology

American congress of Chemotherapy

Asian Society of Chemotherapy

Chemotherapy Group

Northern Chemotherapy Centre

Queensland Centre for Chemotherapy

Industries Associated with Chemotherapy Research

Industries associated with Chemotherapy over all worlds are about 85% in which 12% of industries are in USA and in Dallas about 3%.

Johnson & Johnson

Novartis

Roche

Pfizer

Sanofi

Merck

Bristol-myers squibb

Eli Lilly

Celgene

Takeda

AstraZeneca

Merck & Co.

Amgen

Bayer

Otsuka

Pharmacyclics

Incyte

Universities Associated with Chemotherapy Research

Chemotherapy associated universities in world are about 3284, in USA 612 universities.

The University of Texas at Austin

Texas A&M University

Rice University

University of Houston

University of North Texas

Texas Tech University

The University of Texas at Dallas

Baylor University

Southern Methodist University

The University of Texas at Arlington

Texas State University

The University of Texas MD Anderson Cancer Center

The University of Texas at San Antonio

The University of Texas at El Paso

The University of Texas Medical Branch at Galveston

The University of Texas Health Science Center at San Antonio

Baylor College of Medicine

Lamar University

Sam Houston State University

Texas Christian University

University of Texas Southwestern Medical Center

Trinity University

Stephen F. Austin State University

Texas Tech University Health Sciences Center

Texas Woman's University

St. Edward's University

The University of Texas Health Science Center at Houston

Texas A&M University-Corpus Christi

Texas Southern University

Abilene Christian University

Tarleton State University

Texas A&M International University

Angelo State University

Southwestern University

West Texas A&M University

University of Houston-Clear Lake

Texas A&M University-Kingsville

The University of Texas-Pan American

South Texas College of Law

Midwestern State University

Prairie View A&M University

The University of Texas at Brownsville

St. Mary's University

University of Houston-Downtown

University of Dallas

The University of Texas at Tyler

Dallas Baptist University

University of the Incarnate Word

LeTourneau University

Houston Baptist University

University of Mary Hardin-Baylor

Southwestern Adventist University

Our Lady of the Lake University

Texas A&M University-Commerce

Austin College

Texas A&M University at Galveston

Concordia University Texas

The University of Texas of the Permian Basin

Hardin-Simmons University

University of St. Thomas

McMurry University

Sul Ross State University

Texas Wesleyan University

Wayland Baptist University

University of Houston-Victoria

Schreiner University

Lubbock Christian University

Texas A&M University-Texarkana

East Texas Baptist University

Southwestern Assemblies of God University

Huston-Tillotson University

Jarvis Christian College

Wiley College

Texas Lutheran University

Howard Payne University

Amberton University

Paul Quinn College

Dallas Christian College

The University of Texas Health Science Center at Tyler

Texas College

Arlington Baptist College

College of Biblical Studies

Baptist University of the Americas

Market Value on Chemotherapy Research

The global Chemotherapy market in 2010 was valued at $54bn, an increase of 5.1% over the previous year‘s sales of $51.3bn, and is forecasted to grow at a CAGR of 6.9% from 2010–16, reaching $81bn in 2016.

Collectively, the seven major markets (US, 5EU, and Japan) represented 79.1% (or $43bn) of in the Chemotherapy market  in 2016. In terms of size, the US dominated the Chemotherapy market, with 2016 sales of $21bn and a market share of 38.5%.

The Chemotherapy market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastic and cytostatic hormonal treatments, dominating this sector. Collectively, the leading 10 brands accounted for almost 58.2% (or $31.4bn) of the Chemotherapy market in 2016.

In 2016 antineoplastic was the leading drug class in the Chemotherapy market. The global antineoplastic market was valued at $46bn in 2016 at a year-on-year (Y-o-Y) growth of 7.3%. The major drugs that contributed to the 2016 sales in the antineoplastic category were Roche‘s Avastin (bevacizumab) at $6.2bn, Herceptin (trastuzumab) at $5.2bn, and MabThera (rituximab) at $5.1bn, with Y-o-Y sales growth of 3.8%, 3.1%, and 3.3% respectively.

The cytostatic hormonal market registered 2016 sales of $8bn at a Y-o-Y decline of 6.5%. AstraZeneca‘s Arimidex (anastrozole) and Novartis‘s Femara (letrozole) led this class, reaching sales of $1.5bn and $1.3bn respectively in 2016.

Market Growth of Chemotherapy Research in the last and upcoming ten years

TechNavio's analysts forecast the Global Chemotherapy market to grow at a CAGR of 12.47% over the period 2013-2018. One of the key factors contributing to this market growth is the increase in prevalence of Chemotherapy. The Global Chemotherapy market has also been witnessing the emergence of personalized medicines. However, the increase in use of CAM could pose a challenge to the growth of this market. In next ten years as population ages, the number of people diagnosed with cancer is expected to be double. According to the American Cancer Society, cancer accounts for every 1 of every 4 in U.S deaths, for women it is one in three .The volumes of cancer services continues to grow. Radiation therapy by 3%,infusion therapy by 7% ; Gynecologic services by 10%(annually).With earlier detection, cancer patients will be identified earlier with improvements in chemotherapy, patients will be able to tolerate more treatments, all of which will result in more treatments per patient and more lives saved.

Fund Allotment to Chemotherapy Research

Fund allotted to the individual types of Chemotherapy research in Dollars for Ovarian, Cervical and Uterine cancers 147$, 119$ and 59$ in which Cervical cancer is funded majorly.

Statistics of Physicians, Researchers and Academicians working on Chemotherapy

San Antonio's Biosciences industry employs over 100,000 people. The largest areas of research are conducted by institutes in or around the South Texas Medical Center. These include the Chemotherapy division of one of the world's top five biotechnology firms, the world's largest Phase I clinical trials program for Chemotherapy, and the new $200 million woman’s Cancer Research Institute. Dallas also houses the world's largest genomics computing cluster and the state's public bank for stem cell-rich umbilical cord blood.

Products manufactured by the industry related Chemotherapy Research & their Market Value:

Neosar (Cyclophosphamide) - manufactured by Roxane Laboratories Inc and the market value is17.06$

Paraplat (Carboplatin)-manufactured by Bristol-Myers Squibb Company and the market value is128$

Platinol (Cisplatin)-manufactured by Bristol-Myers Squibb Company and the market value is15.3$

Gemzar (Gemcitabine Hydrochloride)-manufactured by Eli Lilly and Company and the market value is26.1$

Clafen (Cyclophosphamide)-manufactured by Selleckchem and the market value is150$